Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Fleming

Showing results (361-370 of 426) with videos related to

Pageof 43
Sort By:
Urologic Oncology|December 5, 2009
Azacitidine favorably modulates PSA kinetics correlating with plasma DNA LINE-1 hypomethylation in men with chemonaïve castration-resistant prostate cancerGuru Sonpavde, Ana M Aparicio, Feng Zhan, et al.
Breast Cancer Research and Treatment|August 31, 2018
Obesity and mortality after locoregional breast cancer diagnosisA Holliston Moore, Amy Trentham-Dietz, Marguerite Burns, et al.
Clinical Genitourinary Cancer|February 21, 2012
Association of rash with outcomes in a randomized phase II trial evaluating cetuximab in combination with mitoxantrone plus prednisone after docetaxel for metastatic castration-resistant prostate cancerMark T Fleming, Guru Sonpavde, Michael Kolodziej, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 2, 2021
Phase I Study of MEDI3726: A Prostate-Specific Membrane Antigen-Targeted Antibody-Drug Conjugate, in Patients with mCRPC after Failure of Abiraterone or EnzalutamideJohann S de Bono, Mark T Fleming, Judy S Wang, et al.
Lancet (London, England)|September 15, 1999
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trialL A Guay, P Musoke, T Fleming, et al.
Physical Review Letters|November 10, 2015
Detecting Stealth Dark Matter Directly through Electromagnetic PolarizabilityT Appelquist, E Berkowitz, R C Brower, et al.
European Urology Open Science|April 27, 2023
Management of Fibroblast Growth Factor Inhibitor Treatment-emergent Adverse Events of Interest in Patients with Locally Advanced or Metastatic Urothelial CarcinomaArlene O Siefker-Radtke, Andrea Necchi, Se Hoon Park, et al.
The Prostate|January 22, 2019
Phase 1 study of PSMA ADC, an antibody-drug conjugate targeting prostate-specific membrane antigen, in chemotherapy-refractory prostate cancerDaniel P Petrylak, Philip Kantoff, Nicholas J Vogelzang, et al.
The Lancet. Oncology|August 13, 2021
Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trialJohann S de Bono, Niven Mehra, Giorgio V Scagliotti, et al.
The Lancet. Oncology|January 14, 2022
Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 studyArlene O Siefker-Radtke, Andrea Necchi, Se Hoon Park, et al.
Pageof 43

Showing results (361-370 of 426) with videos related to

Sort By:
Pageof 43
Urologic Oncology|December 5, 2009
Azacitidine favorably modulates PSA kinetics correlating with plasma DNA LINE-1 hypomethylation in men with chemonaïve castration-resistant prostate cancerGuru Sonpavde, Ana M Aparicio, Feng Zhan, et al.
Breast Cancer Research and Treatment|August 31, 2018
Obesity and mortality after locoregional breast cancer diagnosisA Holliston Moore, Amy Trentham-Dietz, Marguerite Burns, et al.
Clinical Genitourinary Cancer|February 21, 2012
Association of rash with outcomes in a randomized phase II trial evaluating cetuximab in combination with mitoxantrone plus prednisone after docetaxel for metastatic castration-resistant prostate cancerMark T Fleming, Guru Sonpavde, Michael Kolodziej, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 2, 2021
Phase I Study of MEDI3726: A Prostate-Specific Membrane Antigen-Targeted Antibody-Drug Conjugate, in Patients with mCRPC after Failure of Abiraterone or EnzalutamideJohann S de Bono, Mark T Fleming, Judy S Wang, et al.
Lancet (London, England)|September 15, 1999
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trialL A Guay, P Musoke, T Fleming, et al.
Physical Review Letters|November 10, 2015
Detecting Stealth Dark Matter Directly through Electromagnetic PolarizabilityT Appelquist, E Berkowitz, R C Brower, et al.
European Urology Open Science|April 27, 2023
Management of Fibroblast Growth Factor Inhibitor Treatment-emergent Adverse Events of Interest in Patients with Locally Advanced or Metastatic Urothelial CarcinomaArlene O Siefker-Radtke, Andrea Necchi, Se Hoon Park, et al.
The Prostate|January 22, 2019
Phase 1 study of PSMA ADC, an antibody-drug conjugate targeting prostate-specific membrane antigen, in chemotherapy-refractory prostate cancerDaniel P Petrylak, Philip Kantoff, Nicholas J Vogelzang, et al.
The Lancet. Oncology|August 13, 2021
Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trialJohann S de Bono, Niven Mehra, Giorgio V Scagliotti, et al.
The Lancet. Oncology|January 14, 2022
Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 studyArlene O Siefker-Radtke, Andrea Necchi, Se Hoon Park, et al.
Pageof 43